Modern Optometry
Online/Digital
A resource for optometrists practicing at the top of their license. Medical eye care is the future of optometry and Modern Optometry is your go-to resource for navigating the evolution of the profession. This is a BMC Vision publication. Source
Actions
Media Outlet details
| Scope | N/A |
|---|---|
| Language | English |
| Country | United States of America |
|
Similarweb UVM |
Request pricing |
|
Comscore UVM |
Request pricing |
Recent Articles
Search ArticlesFDA Recalls More than 2.5 Million Bottles of Prednisolone Acetate Eye Drops
Key Takeaways The FDA has classified the nationwide recall of 2.5 million bottles of Lupin's prednisolone acetate eye drops as a Class II recall due to the presence of a foreign substance The recall affects 5-mL, 10-mL, and 15-mL bottles with specific NDCs and numerous lot numbers expiring between July 2026 and March 2028 More than 2.5 million bottles of prednisolone acetate eye drops manufactured by India-based Lupin Limited have been recalled nationwide.
Alcon Survey Highlights Gap Between Parental Concern About Vision and Annual Eye Exams
Key Takeaways An Alcon-commissioned survey found that while 88% of parents believe vision affects academic performance and classroom success, more than one-quarter reported their teen had not received a comprehensive eye exam within the past year or ever The survey also found opportunities to increase education about contact lenses and highlighted eye care professional recommendations as a leading factor motivating parents to schedule annual eye exams As families prepare for the...
Alcon, RxSight Partner to Develop Adjustable Presbyopia-Correcting IOLs
Key Takeaways Alcon and RxSight have entered a non-exclusive collaboration to develop adjustable presbyopia-correcting IOLs by combining Alcon's IOL designs with RxSight's light-adjustable technology The companies aim to create a postoperative adjustable PCIOL platform that enables surgeons to refine visual outcomes after cataract surgery Alcon and RxSight announced they have entered into a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting IOLs (PCIOLs),...
Chinese Study Shows Prediction Model May Help Identify Children at Highest Risk of Developing Myopia
Key Takeaways A prediction model developed from 4 years of school vision screening data successfully identified children at increased risk of developing myopia before disease onset Temporal validation in an independent cohort demonstrated good predictive performance despite differences in baseline characteristics and myopia incidence At a 10% risk threshold, the model could reduce unnecessary preventive interventions by nearly half compared with treating all children while maintaining...
Provectus Biopharmaceuticals and VisiRose Announce US Patent Award for Light-Independent Antibacterial Eye Drop
Key Takeaways Provectus Biopharmaceuticals and VisiRose received a patent award for a topical eye drop formulation of RBS API for treating Gram-positive bacterial keratitis, including drug-resistant strains. The RBS API drop formulation is light-independent, meaning it can potentially be self-administered by patients with the same use pattern as existing prescription antibiotic drops, but for resistant-organism infections those drugs increasingly cannot clear.
Outdoor Artificial Light at Night Linked with Higher Risk of Childhood Myopia in Hong Kong Cohort
Key Takeaways Higher residential outdoor artificial light at night was associated with both greater prevalence of childhood myopia and a 26% increased risk of developing myopia over 3 years The association with incident myopia appeared nonlinear, with risk increasing substantially once nighttime light exposure exceeded approximately 93 nW/cm²/sr Additional longitudinal and mechanistic studies are needed before causal conclusions or public health recommendations can be made Children exposed to...
Addressing Dry Eye Symptoms is Associated With Improved Quality of Life, According to New Data From Bausch + Lomb
Key Takeaways Bausch + Lomb announced findings of its third annual State of Dry Eye survey, conduction online by The Harris Poll in May 2026 among 1,000 participants with dry eye. One in five participants reported dry eye symptoms affect their self-confidence (22%) and emotional wellbeing (20%), and those treated with prescription eye drops versus OTC products were more likely to report substantial improvements in quality of life.
Hengrui Pharma Secures China Approval for Water-Free Cyclosporine Eye Drop for Dry Eye Disease
Key Takeaways China's NMPA approved Heng Yi (0.1% cyclosporine ophthalmic solution) for dry eye disease, marking the first approved water-free cyclosporine ophthalmic solution in the country Phase 3 data demonstrated significant improvements in corneal staining by Day 15 and Day 29, with a favorable safety and tolerability profile in patients with moderate-to-severe DED Hengrui Pharma has received approval from China's National Medical Products Administration (NMPA) for Heng Yi (0.1%...
Optometrist Launches EyeVida Beauty Reminder System
Key Takeaways EyeVida is a new reminder system created by optometrist Melissa Barnett, OD, to help consumers replace cosmetics at recommended intervals using month-labeled stickers The educational initiative highlights evidence linking microbial contamination of aging cosmetics with ocular irritation, inflammation, styes, and other infections Melissa Barnett, OD, FAAO, has launched EyeVida, a beauty product reminder system designed to help consumers replace cosmetics before they become a...
Tenpoint Therapeutics Launches National Consumer Campaign for Yuvezzi
Tenpoint Therapeutics has launched its first national direct-to-consumer campaign for Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, expanding its commercial strategy following the FDA approval of the once-daily prescription eye drop for presbyopia. Called "Friends of the Presbyopians," the campaign uses a cast of handcrafted puppets representing everyday objects commonly associated with the challenges of presbyopia.